Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Company Overview

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.41 to $0.43
• 50-Day Range: $0.39 to $0.59
• 52-Week Range: $0.39 to $2.80
• Volume: 298,991 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $121.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Reduce

Lyell Immunopharma Stock Analysis - MarketRank™

Lyell Immunopharma scored higher than 45% of companies evaluated by MarketBeat, and ranked 412th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyell Immunopharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyell Immunopharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyell Immunopharma has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.07% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Lyell Immunopharma has recently increased by 71.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyell Immunopharma does not currently pay a dividend.

Dividend Growth

Lyell Immunopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.07% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Lyell Immunopharma has recently increased by 71.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.84

News Sentiment

Lyell Immunopharma has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Lyell Immunopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $449,508.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

25.10% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYEL Stock Analysis - Frequently Asked Questions

How have LYEL shares performed this year?

Lyell Immunopharma's stock was trading at $0.64 on January 1st, 2025. Since then, LYEL stock has decreased by 35.9% and is now trading at $0.41.
View the best growth stocks for 2025 here.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its earnings results on Tuesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative trailing twelve-month return on equity of 34.64% and a negative net margin of 323,792.09%.

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

Who are Lyell Immunopharma's major shareholders?

Top institutional shareholders of Lyell Immunopharma include Almitas Capital LLC (0.84%), Charles Schwab Investment Management Inc. (0.54%), Acadian Asset Management LLC (0.22%) and Nuveen LLC (0.22%). Insiders that own company stock include Richard Klausner, Lynn Seely, Sumant Ramachandra, Charles W Newton and Otis W Brawley.
View institutional ownership trends.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyell Immunopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LYEL
• CIK: 1806952
• Web: www.lyell.com
• Phone: 650-695-0677
• Fax: N/A
• Employees: 270
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.00
• High Stock Price Target: $1.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +143.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$234.63 million
• Net Margins: -323,792.09%
• Pretax Margin: -323,792.09%
• Return on Equity: -34.64%
• Return on Assets: -30.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.43
• Quick Ratio: 13.43

Sales & Book Value

• Annual Sales: $65,000.00
• Price / Sales: 1,862.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.60 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 295,338,000
• Free Float: 218,829,000
• Market Cap: $121.09 million
• Optionable: Optionable
• Beta: -0.25